NASDAQ:REPH

Recro Pharma Stock Forecast, Price & News

$2.76
-0.02 (-0.72 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.64
Now: $2.76
$2.80
50-Day Range
$2.54
MA: $3.37
$4.91
52-Week Range
$1.49
Now: $2.76
$9.19
Volume283,435 shs
Average Volume627,547 shs
Market Capitalization$85.60 million
P/E Ratio13.80
Dividend YieldN/A
Beta1.25
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
Recro Pharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470
Employees185
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$99.22 million
Cash Flow$0.54 per share
Book Value($0.30) per share

Profitability

Net Income$-18,630,000.00

Miscellaneous

Market Cap$85.60 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

Recro Reports Inducement Grants for New Staff
April 6, 2021 |  finance.yahoo.com
News for Recro Pharma Inc
March 26, 2021 |  markets.businessinsider.com
Earnings Preview for Recro Pharma
February 25, 2021 |  finance.yahoo.com
Revisiting Recro Pharma
February 17, 2021 |  seekingalpha.com
Recro Grants Inducement Award to New Chief Executive Officer
December 18, 2020 |  finance.yahoo.com
Recro Announces Executive Changes
December 16, 2020 |  finance.yahoo.com
Oppenheimer Says These 2 Stocks Could Spike Over 100%
December 11, 2020 |  finance.yahoo.com
Recro Pharma (REPH) Q3 2020 Earnings Call Transcript
November 9, 2020 |  finance.yahoo.com
Recro Pharma, Inc. (REPH)
August 10, 2020 |  ca.finance.yahoo.com
Recro Pharma EPS misses by $0.09, misses on revenue
August 10, 2020 |  seekingalpha.com
Recro Reports Second Quarter 2020 Financial Results
August 10, 2020 |  finance.yahoo.com
Recro Pharma: Q2 Earnings Insights
August 10, 2020 |  finance.yahoo.com
Is Recro Pharma Inc (REPH) A Good Stock To Buy?
July 5, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

185th out of 2,025 stocks

Pharmaceutical Preparations Industry

80th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
$2.76
-0.02 (-0.72 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

Is Recro Pharma a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Recro Pharma stock.
View analyst ratings for Recro Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Recro Pharma?

Wall Street analysts have given Recro Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Recro Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Recro Pharma
.

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) posted its quarterly earnings data on Friday, February, 26th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.22. The specialty pharmaceutical company earned $9.91 million during the quarter.
View Recro Pharma's earnings history
.

How has Recro Pharma's stock price been impacted by COVID-19?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REPH shares have decreased by 69.9% and is now trading at $2.76.
View which stocks have been most impacted by COVID-19
.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma issued an update on its first quarter 2021 Pre-Market earnings guidance on Friday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16.356-16.852 million, compared to the consensus revenue estimate of $17.64 million.

What price target have analysts set for REPH?

2 brokers have issued twelve-month price objectives for Recro Pharma's stock. Their forecasts range from $12.00 to $12.00. On average, they expect Recro Pharma's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 334.8% from the stock's current price.
View analysts' price targets for Recro Pharma
or view top-rated stocks among Wall Street analysts.

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 44, Pay $572.13k)
  • Mr. J. David Enloe Jr., Pres, CEO & Director (Age 57)
  • Mr. Randall J. Mack, Sr. VP of Devel. (Age 56)
  • Mr. Marshall Rizzo M.B.A., Sr. VP & Gen. Mang.
  • Dr. Jyrki Mattila, Exec. VP of Bus. Devel. (Age 66)
  • Carla Lusby, Corp. Sec.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Clear Harbor Asset Management LLC (0.38%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood and Scp Vitalife Partners (Israel).
View institutional ownership trends for Recro Pharma
.

Which major investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Clear Harbor Asset Management LLC.
View insider buying and selling activity for Recro Pharma
or or view top insider-buying stocks.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $2.76.

How much money does Recro Pharma make?

Recro Pharma has a market capitalization of $85.60 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis.

How many employees does Recro Pharma have?

Recro Pharma employs 185 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

Where are Recro Pharma's headquarters?

Recro Pharma is headquartered at 490 LAPP ROAD, MALVERN PA, 19355.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.